Toll-Like Receptor Agonists

Agents that stimulate TOLL-LIKE RECEPTOR signaling, and the activity of both the INNATE IMMUNE RESPONSE and ADAPTIVE IMMUNITY.

Also Known As:

Agonist, Toll-Like Receptor; Agonists, TLR; Agonists, Toll-Like Receptor; Receptor Agonist, Toll-Like; Receptor Agonists, Toll-Like; Toll Like Receptor Agonist; Toll Like Receptor Agonists; TLR Agonists; Toll-Like Receptor Agonist

Networked: 604 relevant articles (46 outcomes, 85 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Toll-Like Receptor Agonists: 604
  - Physiological Effects of Drugs: 1
    - Immunologic Factors: 7984
      - Immunomodulating Agents: 2530
        Toll-Like Receptor Agonists: 604

Experts

1.	Zitvogel, Laurence: 9 articles (01/2018 - 10/2008)
2.	Galluzzi, Lorenzo: 8 articles (01/2018 - 08/2012)
3.	Kroemer, Guido: 8 articles (01/2018 - 08/2012)
4.	Evans, Scott E: 6 articles (12/2020 - 01/2012)
5.	Eggermont, Alexander: 6 articles (03/2016 - 08/2012)
6.	Sautès-Fridman, Catherine: 6 articles (01/2014 - 08/2012)
7.	Sabroe, Ian: 6 articles (09/2009 - 04/2005)
8.	Slingluff, Craig L: 5 articles (01/2021 - 09/2011)
9.	Dickey, Burton F: 5 articles (12/2020 - 01/2012)
10.	Mills, Kingston H G: 5 articles (10/2014 - 03/2008)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2022 - "Although a few TLR agonists have been approved for the treatment of patients with early-stage superficial cancers, their therapeutic efficacy is limited in patient with advanced invasive cancers. " 04/01/2015 - "Finally, our results indicated that the enhancement of iNOS expression through the administration with TLR agonists impairs host anti-tumor immunity, while the inhibition of iNOS could enhance the therapeutic efficacy of TLR agonists via the increase in Th1 immune response." 04/01/2015 - "Our results indicated that the enhancement of IDO expression with TLR agonists in cancer treatment might impair host anti-tumour immunity while the inhibition of IDO could enhance the therapeutic efficacy of TLR agonists via the increase of T helper type 1 immune response. " 02/01/2014 - "Improved molecular profiling of lymphoid malignancies may give new insights into pathogenesis of these cancers and pave the way for novel therapeutic agents, including TLR agonists. " 01/01/2023 - "All our data suggest that coupling and co-delivery are required to enhance the anti-tumor efficacy of TLR agonists and simple mixing of the VLPs with the agonists does not confer a survival benefit. "
2.	Infections 01/01/2010 - "Current data indicate Toll-like receptor agonists and selected immunomodulating compounds effectively increase the HSV infection threshold and hold promise for genital prophylaxis. " 12/01/2008 - "Furthermore, IAV infection and exposure to TLR agonists relieved the suppressive activity of MDSCs. " 07/07/2023 - "In this study, we used punch-excised teat tissue as an ex vivo model to study the immune mechanisms that arise early during infection when bacteria have entered the MG. Cytotoxicity and microscopic analyses showed that bovine teat sinus explants have their morphology and viability preserved after 24 h of culture and respond to ex vivo stimulation with TLR-agonists and bacteria. " 01/15/2007 - "Different TLR agonists can profoundly alter inflammatory effects of one another, and studies suggest that the sequence of exposure to TLR agonists may importantly impact on responses during infection. " 01/01/2023 - "DCs undergo metabolic reprogramming following exposure to TLR agonists, which is thought to be a prerequisite for a successful host response to infection. "
3.	Communicable Diseases (Infectious Diseases) 01/01/2014 - "TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious Disease." 01/01/2008 - "Recently, TLR agonists represent a promising approach for the treatment of infectious diseases. " 11/01/2013 - "This supplement of the Journal of Infectious Diseases summarizes work in the humanized mouse model presented at an HIV Humanized Mouse workshop in Boston, Massachusetts, in November 2012, including recent advances in the development of humanized mice, the trafficking of human immune cells following mucosal HIV transmission, the role of immune activation and Toll-like receptor agonists in the control of HIV, the induction and efficacy of HIV-specific cellular and humoral immune responses, and the preclinical modeling of novel anti-HIV therapeutics. " 11/18/2013 - "Here we focus on studies developing TLR agonists and antagonists for the treatment of infectious diseases and sepsis. " 02/16/2022 - "Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases."
4.	Inflammation (Inflammations) 01/01/2022 - "However, TLR agonists in free form are prone to be eliminated quickly by the circulatory system and cause systemic inflammation side effects. " 03/10/2023 - "CLP and TLR agonists increase gut and systemic inflammation. " 09/19/2022 - "However, IT delivery of TLR agonists may lead to rapid effusion from the tumor microenvironment (TME), potentially limiting the duration of local inflammation and increasing the risk of systemic adverse events. " 01/01/2021 - "Lung explants were stimulated with different TLR agonists or infected with the human airways pathogen, respiratory syncytial virus (RSV), resulting in greater inflammation under almost all conditions for the GF explants. " 01/01/2019 - "In addition, blood samples were stimulated or not with various TLR agonists to evaluate whether RA-dependent chronic inflammation can lead to immune-cell exhaustion. "
5.	Melanoma (Melanoma, Malignant) 12/01/2006 - "We report a new immunological treatment for advanced cutaneous melanoma which combines laser stimulation with topical application of a toll-like receptor agonist. " 08/01/2022 - "Increased understanding of tumor immune mechanisms has led to attract more attention for the potential of TLR agonists on treatment of melanoma. " 01/01/2017 - "Alveolar macrophages from melanoma lung metastases-bearing mice, treated with aerosolized TLR agonists, also promoted NK cell cytotoxicity. " 02/01/2023 - "In this study, the combination of AgNP and resiquimod (RSQ: a Toll-like receptor agonist) was investigated and shown to significantly prolong the survival of melanoma-challenged mice when added sequentially. " 03/01/2015 - "We describe the implementation of an adaptive design for identifying the optimal treatment strategy in a multi-site, FDA-approved, phase I/II trial of a novel vaccination approach using long-peptides plus TLR agonists for resected stage IIB-IV melanoma. "

Related Drugs and Biologics

1.	Vaccines
2.	Toll-Like Receptors (Toll-Like Receptor)
3.	Antigens
4.	Peptides (Polypeptides)
5.	Cytokines
6.	Cancer Vaccines
7.	Neoplasm Antigens (Tumor Antigens)
8.	Protein Subunit Vaccines
9.	DNA (Deoxyribonucleic Acid)
10.	Interleukin-10 (Interleukin 10)

Related Therapies and Procedures

1.	Immunotherapy
2.	Therapeutics
3.	Drug Therapy (Chemotherapy)
4.	Immunomodulation
5.	Radiotherapy